Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406228 | 0.91 | AOC3 (0.41) | AOC3DGAT1KCNH2ADORA2APDE4A | |
| SCHEMBL2411687 | 0.91 | DGAT1 (0.41) | MGLLAOC3DGAT1KCNH2EGLN1 | |
| SCHEMBL2407424 | 0.88 | MCHR1 (0.43) | AOC3DGAT1KCNH2PDE4APDE4B | |
| SCHEMBL2404039 | 0.86 | DGAT1 (0.41) | DGAT1KCNH2ADORA2A | |
| SCHEMBL2408002 | 0.84 | TRPM8 (0.41) | AOC3DGAT1 | |
| SCHEMBL2406534 | 0.84 | DGAT1 (0.42) | DGAT1KCNH2EGLN1 | |
| SCHEMBL2406077 | 0.82 | PDE10A (0.45) | DGAT1KCNH2ADORA2AGRM5 | |
| SCHEMBL2329208 | 0.75 | CNR2 (0.54) | CNR2MGLLDGAT1KCNH2EGLN1 | |
| SCHEMBL2431551 | 0.74 | MCHR1 (0.39) | DGAT1KCNH2ADORA2A | |
| SCHEMBL2406147 | 0.73 | AOC3 (0.38) | AOC3DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912218-B2 | Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | CNR2 86/4885MGLL 2325/4885AOC3 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.